{rfName}
A

Indexed in

Citations

4

Altmetrics

Analysis of institutional authors

Gonzalez-Escalada, ACorresponding AuthorMarin-Garcia, PAuthorGil-De-Miguel, AAuthorGil-Prieto, RAuthor

Share

September 27, 2022
Publications
>
Article
No

A Comparison of Two Enzyme Immunoassay Tests for the Detection of IgG Antibodies for Measles Virus

Publicated to: Clinical Laboratory. 60 (1): 69-71 - 2014-01-01 60(1), DOI: 10.7754/Clin.Lab.2013.121207

Authors:

González-Escalada, A; Marín-Garcia, P; Gil-De-Miguel, A; Gil-Prieto, R
[+]

Affiliations

Univ Rey Juan Carlos, Dept Med Immunol & Microbiol, Madrid 28922, Spain - Author
Univ Rey Juan Carlos, Dept Prevent Med & Publ Hlth, Madrid 28922, Spain - Author

Abstract

Background: Despite the reduction in the incidence of measles in recent years, outbreaks have appeared in various countries in Central and Western Europe. Estimating the percentage of immune individuals is fundamental for establishing control strategies in these situations. Methods: A total of 1,147 serum samples from healthy volunteers were tested by two commercial enzyme immunoassay (EIA) tests that detect antibodies for the measles virus: Enzygnost Anti-Measles Virus/IgG (Siemens, Marburg, Germany) and VIDAS Measles IgG (bioMerieux, Inc.). The following values were calculated for each test: sensitivity, specificity, positive and negative predictive values, and likelihood ratios. Results: Compared to the Enzygnost test, the sensitivity of the VIDAS test was 98.0% and the specificity was 78.1%. The likelihood ratio (LR) values were +4.48, -0.025 and +/-0.17. Conclusions: The VIDAS Measles IgG test is a quick method with good sensitivity for detecting IgG antibodies for the measles virus compared to the Enzygnost EIA test.
[+]

Keywords

Antibodies, viralAustraliaEnzyme immunoassayEuropean countriesHealthy volunteersHumansIggImmunoenzyme techniquesImmunoglobulin gLimit of detectionMeaslesMeasles virus

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Laboratory due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2014, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Biochemistry, Genetics and Molecular Biology (Miscellaneous). Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Medical Laboratory Technology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 2
  • Scopus: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 12 (PlumX).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (González-Escalada Mena, María del Alba) and Last Author (Gil Prieto, Ruth).

the author responsible for correspondence tasks has been González-Escalada Mena, María del Alba.

[+]

Awards linked to the item

This project was funded by The Health Research Fund grant PS09/02331, Ministerio de Sanidad, Instituto de Salud Carlos III (Ministry of Health, Institute of Health Carlos III, Spain).
[+]